Studies have shown that ADAMTS-13 can inhibit oxidative stress and improve the progression of chronic kidney disease after ischemia/reperfusion injury, while rhADAMTS-13 can inhibit ROS level, improve microvascular dysfunction, inhibit GSK3β activity and upregulate the expression of Nrf2 [15]. The gene discussed is ADAMTS13; the disease is chronic kidney disease.